NASDAQ · OABIW
OmniAb, Inc.
$0.08 -$0.00 (-1.98%) 1DKey Metrics
$8.38M
Market cap
—
P/E · TTM
$28.94M
Revenue · TTM
−$54.29M
Net income
EPS · TTM
$-0.51
Dividend yield
—
Free cash flow
−$26.02M
Beta · 1Y
—
EBITDA · TTM
−$40.34M
Gross margin
—
Snapshot
Market cap—
Enterprise value—
Shares outstanding—
52-wk range$0.05 – $0.29
Avg volume · 20D29.4K
Net cash
—
Book value / share$2.49
IndustryServices-Commercial Physical & Biological Research
ExchangeNASDAQ
About OmniAb, Inc.
IPO dateNov 1, 2022
Employees89
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S0.29
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
-200.3%
Net
-187.6%
FCF
-89.9%
ROE / ROIC
-19.7% · -26.7%
Financial Health
Current ratio4.80
Quick ratio4.73
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$51.56M
Cash Flow · TTM
Operating CF
−$25.50M
Capex
−$523.00K
Free cash flow
−$26.02M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
1 / 9
Weak fundamentals · 1 of 9 signals passing
Altman Z-Score
-1.0
Distress zone (< 1.81) · elevated risk
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings